The functional interaction between acyl-coa synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: A novel therapeutic target

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Orlando, Ulises D ^a   Garona, Juan ^b   Ripoll, Giselle V ^b   Maloberti, Paula M ^a   Solano, Ángela R ^a   Avagnina, Alejandra ^c   Gomez, Daniel E ^b   Alonso, Daniel F ^b   Podestá, Ernesto J ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c CEMIC   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; DOCEBENONE; DOXYCYCLINE; ESTROGEN RECEPTOR; ETORICOXIB; IBUPROFEN; LIPOXYGENASE; LIPOXYGENASE 5; LONG CHAIN FATTY ACID COENZYME A LIGASE; LONG CHAIN FATTY ACID COENZYME A LIGASE 4; PROGESTERONE RECEPTOR; ROSIGLITAZONE; TRIASIN C; TROGLITAZONE; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFORMATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MITOSIS INDEX; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; COENZYME A LIGASES; CYCLOOXYGENASE 2; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MCF-7 CELLS; MICE; MOLECULAR TARGETED THERAPY; RECEPTORS, PROGESTERONE; TETRACYCLINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84863767880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040794     Document Type: Article

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR, (2005) Molecular evolution of breast cancer. J Pathol 205: 248-254.
3. Bertucci F, Birnbaum D, (2008) Reasons for breast cancer heterogeneity. J Biol 7: 6.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
5. Wang MT, Honn KV, Nie D, (2007) Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26: 525-534.
6. Hyde CA, Missailidis S, (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 9: 701-715.
7. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, et al. (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 26: 503-524.
8. Gonzalez-Periz A, Claria J, (2007) New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr Top Med Chem 7: 297-309.
9. Avis I, Hong SH, Martinez A, Moody T, Choi YH, et al. (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. Faseb J 15: 2007-2009.
10. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, et al. (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681.
11. Kundu N, Yang Q, Dorsey R, Fulton AM, (2001) Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 93: 681-686.
12. Kundu N, Fulton AM, (2002) Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62: 2343-2346.
13. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, et al. (2001) Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569.
14. Narko K, Zweifel B, Trifan O, Ristimaki A, Lane TF, et al. (2005) COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat 76: 86-94.
15. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, et al. (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 101: 591-596.
16. Thun MJ, Henley SJ, Patrono C, (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266.
17. Robertson FM, Mallery SR, Bergdall-Costell VK, Cheng M, Pei P, et al. (2007) Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res 27: 719-727.
18. Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK, et al. (2010) Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity. Transl Oncol 3: 91-98.
19. Sung YK, Hwang SY, Park MK, Bae HI, Kim WH, et al. (2003) Fatty acid-CoA ligase 4 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94: 421-424.
20. Cao Y, Dave KB, Doan TP, Prescott SM, (2001) Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res 61: 8429-8434.
21. Maloberti PM, Duarte AB, Orlando UD, Pasqualini ME, Solano AR, et al. (2010) Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells. PLoS One 5: e15540.
22. Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, et al. (1997) A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. Proc Natl Acad Sci U S A 94: 2880-2884.
23. Soupene E, Kuypers FA, (2008) Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233: 507-521.
24. Anderson WA, Perotti ME, McManaway M, Lindsey S, Eckberg WR, (1984) Similarities and differences in the ultrastructure of two hormone-dependent and one independent human breast carcinoma grown in athymic nude mice: comparison with the rat DMBA-induced tumor and normal secretory mammocytes. J Submicrosc Cytol 16: 673-690.
25. Elston CW, Ellis IO, Pinder SE, (1998) Prognostic factors in invasive carcinoma of the breast. Clin Oncol (R Coll Radiol) 10: 14-17.
26. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, et al. (2010) The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) 4: 35-41.
27. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM, (2000) Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 97: 11280-11285.
28. Askari B, Kanter JE, Sherrid AM, Golej DL, Bender AT, et al. (2007) Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages. Diabetes 56: 1143-1152.
29. Chen X, Wang S, Wu N, Sood S, Wang P, et al. (2004) Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 10: 6703-6709.
30. Fegn L, Wang Z, (2009) Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. J Laryngol Otol 123: 880-884.
31. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, et al. (2005) Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11: 1618-1628.
32. Smith WL, DeWitt DL, Garavito RM, (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182.
33. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, et al. (2011) Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 109: 2742-2747.
34. Minami CA, Chung DU, Chang HR (2011) Management options in triple-negative breast cancer. Breast Cancer (Auckl) 5: 175-199.
35. Cellai I, Petrangolini G, Tortoreto M, Pratesi G, Luciani P, et al. (2010) In vivo effects of rosiglitazone in a human neuroblastoma xenograft. Br J Cancer 102: 685-692.
36. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, et al. (2010) Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer 17: 169-177.
37. Al-Alem L, Southard RC, Kilgore MW, Curry TE, (2011) Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARgamma independent manner. PLoS One 6: e16179.
38. Drzewoski J, Drozdowska A, Sliwinska A, (2011) Do we have enough data to confirm the link between antidiabetic drug use and cancer development? Pol Arch Med Wewn 121: 81-87.
39. Scoditti E, Massaro M, Carluccio MA, Distante A, Storelli C, et al. (2010) PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium. Cardiovasc Res 86: 302-310.
40. Kim KY, Kim SS, Cheon HG, (2006) Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 72: 530-540.
41. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS, (2006) Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13: 401-413.
42. Day C, (1999) Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 16: 179-192.
43. Wei S, Yang J, Lee SL, Kulp SK, Chen CS, (2009) PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 276: 119-124.
44. Fryer LG, Parbu-Patel A, Carling D, (2002) The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226-25232.
45. Kim JH, Lewin TM, Coleman RA, (2001) Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J Biol Chem 276: 24667-24673.
46. Van Horn CG, Caviglia JM, Li LO, Wang S, Granger DA, et al. (2005) Characterization of recombinant long-chain rat acyl-CoA synthetase isoforms 3 and 6: identification of a novel variant of isoform 6. Biochemistry 44: 1635-1642.
47. Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, et al. (2001) Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097.
48. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, et al. (2005) Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 67: 1342-1348.
49. Akinyeke TO, Stewart LV, (2011) Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARgamma-independent mechanism. Cancer Biol Ther 11: 1046-1058.
50. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
51. Alvarez-Diaz S, Larriba MJ, Lopez-Otin C, Munoz A, (2010) Vitamin D: Proteases, protease inhibitors and cancer. Cell Cycle 9: 32-37.
52. Larkins TL, Nowell M, Singh S, Sanford GL, (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6: 181.
53. Perera Y, Farina HG, Hernandez I, Mendoza O, Serrano JM, et al. (2008) Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer 122: 57-62.
54. Ripoll GV, Giron S, Krzymuski MJ, Hermo GA, Gomez DE, et al. (2008) Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. Anticancer Res 28: 2607-2611.
55. Eisenberg E, Levanon EY, (2003) Human housekeeping genes are compact. Trends Genet 19: 362-365.